Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CL. Lustberg MB, et al. Among authors: mrozek e. Clin Breast Cancer. 2011 Aug;11(4):221-7. doi: 10.1016/j.clbc.2011.03.022. Epub 2011 May 19. Clin Breast Cancer. 2011. PMID: 21729671 Free PMC article. Clinical Trial.
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL. Lustberg MB, et al. Among authors: mrozek e. Cancer Chemother Pharmacol. 2012 Jul;70(1):49-56. doi: 10.1007/s00280-012-1887-x. Epub 2012 May 22. Cancer Chemother Pharmacol. 2012. PMID: 22729159 Free PMC article. Clinical Trial.
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.
Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CL. Layman RM, et al. Among authors: mrozek e. Cancer Chemother Pharmacol. 2013 May;71(5):1183-90. doi: 10.1007/s00280-013-2112-2. Epub 2013 Feb 21. Cancer Chemother Pharmacol. 2013. PMID: 23430121 Free PMC article. Clinical Trial.
Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.
Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CL. Mrózek E, et al. Clin Breast Cancer. 2014 Aug;14(4):228-34. doi: 10.1016/j.clbc.2014.02.005. Epub 2014 Feb 20. Clin Breast Cancer. 2014. PMID: 24703985 Free PMC article. Clinical Trial.
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Hicks M, Macrae ER, Abdel-Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Hicks M, et al. Among authors: mrozek e. Oncologist. 2015 Apr;20(4):337-43. doi: 10.1634/theoncologist.2014-0334. Epub 2015 Mar 2. Oncologist. 2015. PMID: 25732265 Free PMC article.
49 results